Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FKC289 in Relapsed/Refractory Primary AL Amyloidosis
NCT07765524Phase 2Not yet recruiting
- Sponsor
- Fosun Kairos
- Start
- Aug 2026
- Primary completion
- Mar 2028
- Countries
- 1
01
Overview
A Phase 2 trial of FKC289 in Amyloid Light Chain Amyloidosis, sponsored by Fosun Kairos. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
FKC289
03
Conditions
Amyloid Light Chain Amyloidosis
Beyond the preview
Go deeper on NCT07765524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07765524.